

Housekeeping

- Please stay on \boldsymbol{mute} during the webinar
- You can ask questions anytime during the webinar using the $\ensuremath{\mathbf{Q+A}}$ function
 - Any question is fine and will be answered at the end of the session $% \left(1\right) =\left(1\right) \left(1$
 - You can upvote questions that you want answered first
 - $\bullet \ \ \text{You can also ask questions verbally at the end of the session-please use the hand function if able}$
- Confidentiality is a must These sessions will be recorded and available in a public format
- Respect one another
 - $\bullet\,$ This is a collaborative, non-judgemental learning environment for everyone

Pacific Diabetes Management Course 2025

2



- · HbA1c
- Blood + interstitial glucose levels
- · Time in range
- Fructosamine

Pacific Diabetes Management Course 202

4

HbA1c

- Most practical target as reflects average glucose levels over the previous 3 months
- The 'target' HbA1c should be individualised + reviewed at least annually
- $^{\circ}\,$ HbA1c should be measured 3 monthly until target + then 6 monthly once at target
- Measurement of HbA1c may be an unreliable target in the following scenarios:
- Acute deterioration in glucose levels
- Any haemoglobinopathy e.g. thalassaemia, sickle cell anaemia
- Altered red cell turnover e.g. pregnancy, bleeding, iron deficiency, haemolysis etc.
- Post blood transfusion

Pacific Diabetes Management Course 2025

5

HbA1c

Most practical target as reflects average glucose levels over the previous 3 months

If HbA1c is unreliable then either blood glucose levels or CGM are the best glycaemic targets. Fructosamine is now rarely used but can be useful alternative to HbA1c

- Measurement of HbA1c may be an unreliable target in the following scenarios:
- Acute deterioration in glucose levels
- Any haemoglobinopathy e.g. thalassaemia, sickle cell anaemia
- · Altered red cell turnover e.g. pregnancy, bleeding, iron deficiency, haemolysis etc.
- Post blood transfusion

Pacific Diabetes Management Course 2025


What should the target HbA1c be?

- The target HbA1c in most patients with diabetes is < 53 mmol/mol (7%)
- Target HbA1c < 48 mmol/mol (6.5%) is appropriate when the risk of hypoglycaemia is low AND if:


 - Young AND/OR
 Considering pregnancy or pregnant AND/OR
 Have diabetic microvascular complications particularly retinopathy + nephropathy
- A higher target HbA1c e.g. 54 70 mmol/mol (7 8.5%) is likely more appropriate if:
 Risk of hypoglycaemia > benefits of tight glycaemic control
 Life expectancy is limited by non-diabetes related comorbidities


 - Frail and/or elderly and/or cognitive impairment and/or functionally dependent


7



8







11


When should people monitor their glucose levels?


- Minimal recommended monitoring includes:
 - Whenever symptomatic of hypoglycaemia or hyperglycaemia → including if discrepancy from CGM
 - At least 3 4 times per day when unwell
 - · Before they drive if on insulin and/or sulfonylureas
 - Fasting glucose levels whilst titrating basal insulin at night
 - Pre + 3-4 hours post meals whilst titrating sulfonylurea or bolus/premixed insulin at that meal (before meals + before bed typically suffices)

 Pre + 1 or 2 hours post all meals in pregnancy
- People should also be encouraged to check glucose levels at other times as powerful educational tool
 - Checking levels before meals + bed on 1-2 days per week often preferable to sporadic checks

When should people monitor their glucose levels?
Minimal recommended monitoring includes:
 Whenever symptomatic of hypoglycaemia or hyperglycaemia → including if discrepancy from CGM
CGM overcomes many of the limitations/difficulties
of blood glucose monitoring
of blood glucose monitoring
of blood glucose monitoring The Administration post means winds unduring sundividual of county premises meaning and the count

Blood pressure targets + management







17

Blood pressure targets

- Blood pressure targets should be individualised & dependent on presence of complications + CV risk
 - If no microvascular or macrovascular complications AND 5 year CVD risk < 5%
 → target BP < 140/90 mmHg

 - → target BP < 140/90 mmHg

 If microvascular Obmacrovascular complications OR 5 year CVD risk > 10%

 → target systolic BP 120 129 mmHg

 Low threshold for treating BP 130 133/80 89 mmHg if 5 year CV risk 5 9.9% in absence of complications

 A systolic BP < 120 mmHg is not concerning if well tolerated + likely preferable if young or heart failure

 Target should be relaxed to lowest reasonable and safely achievable if:

 Frail and/or limited life expectancy

 Aga ≥ 85 years

 Postural hypotension e.g. diabetic autonomic neuropathy

 Diastolic BP is no longer a primary target

Management of high blood pressure

- Healthy living interventions important at all time \rightarrow may reduce BP by ~ 10 mmHg

 - Smoking, vaping + alcohol cessation
 Low salt intake < 2 g of sodium or < 5 g of salt per day
 - Leafy green vegetables + fruit per day to ensure adequate potassium intake
 - Mediterranean diet + Dietary Approaches to Stop Hypertension (DASH) are eating patterns with best long-term evidence

 - · Increased physical activity + movement

 - Interventions for weight loss if overweight

 Sistotal body weight loss will improve blood pressure

 ~10-15% total body weight loss often required for remission of hypertension

19

Management of high blood pressure

- Pharmacological management of hypertension is required if BP remains above target
- Choice of BP lowering agent dependent on presence of renal disease \to particularly albuminuria (UACR > 3 mg/mmol):
 - If renal disease → start ACEi OR ARB + increase to maximal tolerated dose

 - Do not use ACEi + ARB in combination + ensure effective contraception in women of child bearing age
 - If no renal disease \Rightarrow low dose calcium channel blocker AND ACEi OR ARB in combination

 - ACEi/ARB do not prevent renal disease

20

Management of high blood pressure

- · Benefits of each family of medications are 'class effects'
- · Likely best medications available in each class:

 - ACEI OR ARB candesartan likely preferable to enalapril

 CCB felodipine likely preferable

 Thiazide chlorthalidone likely preferable but bendrofluazide good alternative
- Review patients at least 3 monthly until blood pressure to target \rightarrow use opportunity to optimise other management
 - Consider secondary causes of hypertension particularly if treatment resistant or patient is < 35 years of age

Lipid targets + management					
Pacific Diabetes Management Course 2025					

Management of dyslipidaemia

- Healthy living interventions for dyslipidaemia important at all times
 - Avoid trans fats and reduce saturated fats + oils (e.g. coconut, lard, butter)
 - · Limit processed + deep-fried foods
 - · Unsaturated fats + oils (e.g. canola, rice, bran, avocado, olive oil etc.) may be useful alternatives
 - Increase intake of fruits, vegetables + wholegrain foods that bind excess cholesterol e.g. oats, barley, quinoa etc.


 - Physical activity + movement will lower LDLc + TG & increase HDLc
 - Weight loss important if overweight
 - 10-15% weight loss may be required for remission but often strong genetic component of dyslipidaemia

23

Management of dyslipidaemia

- * Statins are recommended if any microvascular or macrovascular complications OR if 5 year CVD risk $\geq 10\%$
 - Target LDLc is < 1.4 mmol/L

 - Secondary targets include triglycerides < 1.8 mmol/L if CV disease + < 5.7 mmol/L if no CV disease Statins also strongly recommended if 5 year CVD risk > 5% with target LDLc < 1.8 mmol/L
- * Simvastatin is often ineffective in people with diabetes due to short half-life
- Consider rosuva statin or ezetimibe if targets not reached on maximal tolerated doses of a torvastatin $\,$
 - Many people with diabetes will qualify for SA for rosuvastatin due to ethnicity and/or CV risk
 - Consider fibrates if TG + LDLc remain above target
 - PSKC9 inhibitors very effective but very expensive!



Management of dyslipidaemia

- $^{\circ}\,$ Ideally monitor non-fasting lipid studies 3 monthly + titrate therapy until LDLc < 1.4 mmol/L
- Definitive adverse effects of statins still relatively rare + ensure adequate contraception but teratogenicity low
- · Atorvastatin + rosuvastatin can be taken at any time of the day & have similar safety profiles

26

Take home messages

- HbA1c is best pragmatic glycaemic target in most with T2D but has limitations
 Target HbA1c < 53 mmo//mol in most

 - Regular glucose levels will always provide the best information
- Effective control of blood pressure critical in prevention, delaying + slowing diabetic
 - Target systolic BP 120 129 mmHg in most if complications or high risk
 If renal disease then start ACEi/ARB + increase to maximal tolerated dose
- Effective control of dyslipidaemia also important in prevention, delaying + slowing diabetic complications
 Target LDL < 1.4 mmol/L in most if complications or high risk
 Atorvastatin or rosuvastatin +/- ezetimibe often required to reach targets in diabetes

Take home messages						
 Target Hb 	t pragmatic glycaemic target in most with T2D but has limitations A1c < 53 mmol/mol in most lucose levels will always provide the best information					
Healthy living interventions are always important in addition to pharmacological management						
e Heatt						
in a	ddition to pharmacological management					
in a	ddition to pharmacological management					
in a • Effective con complication • Target LD	ddition to pharmacological management trol of dyslipidaemia also important in prevention, delaying + slowing diabetics					



Case for discussion – Mr W 33 year old man with 10 year history of type 2 diabetes with HbA1c currently 52 mmol/mol on metformin alone Known retinopathy BP 138/82 mmHg & LDLc 3.2 mmol/L + TG 6.7 mmol/L BMI 38 kg/m² What non-pharmacological + pharmacological management would you suggest? Would you add another glucose-lowering therapy? How often will you follow him up?

Discussion	
Discussion	
Pacific Diabetes Management Course 2025	